GLOBUS MEDICAL ($GMED) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of $1.12 per share, beating estimates of $0.94 by $0.18. The company also reported revenue of $759,850,000, beating estimates of $751,739,051 by $8,110,949.
Stock price change since market close: +5.81%
You can see Quiver Quantitative's $GMED stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
GLOBUS MEDICAL Insider Trading Activity
GLOBUS MEDICAL insiders have traded $GMED stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- KELLY HULLER (EVP, GC, Corporate Secretary) has made 0 purchases and 3 sales selling 37,500 shares for an estimated $3,441,700.
- DAVID D DAVIDAR sold 25,000 shares for an estimated $2,150,005
- STEPHEN T ZARRILLI sold 25,000 shares for an estimated $2,107,257
- KYLE KLINE (Senior Vice President, CFO) has made 0 purchases and 2 sales selling 22,136 shares for an estimated $2,032,133.
- ANN D RHOADS has made 0 purchases and 2 sales selling 10,000 shares for an estimated $818,000.
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,000 shares for an estimated $557,600.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
GLOBUS MEDICAL Hedge Fund Activity
We have seen 279 institutional investors add shares of GLOBUS MEDICAL stock to their portfolio, and 278 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. added 3,595,339 shares (+1235.2%) to their portfolio in Q4 2025, for an estimated $313,909,048
- BANK OF MONTREAL /CAN/ added 3,351,380 shares (+15317.1%) to their portfolio in Q4 2025, for an estimated $292,608,987
- CITADEL ADVISORS LLC added 2,427,303 shares (+2165.4%) to their portfolio in Q4 2025, for an estimated $211,927,824
- HAWK RIDGE CAPITAL MANAGEMENT LP removed 1,569,235 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $137,009,907
- VAN BERKOM & ASSOCIATES INC. removed 1,333,111 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $116,393,921
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 1,104,755 shares (+129818.4%) to their portfolio in Q4 2025, for an estimated $96,456,159
- FULLER & THALER ASSET MANAGEMENT, INC. added 1,035,518 shares (+inf%) to their portfolio in Q4 2025, for an estimated $90,411,076
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
GLOBUS MEDICAL Government Contracts
We have seen $1,115,897 of award payments to $GMED over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- 4568294217!CREO STABILIZATION SYSTEM: $36,585
- PRECICE 2 NAIL / VARIOUS: $32,065
- A GLOBUS PRECISE INTRAMEDULLARY NAIL SYSTEM IS REQUIRED FOR A PATIENT (FOR LIMB LENGTHENING SURGERY): $32,065
- PRECLCE LNTRAMEDULLARY LIMB LENGTHENING SYSTEM INTENDED FOR THE LIMB LENGTHENING OF THE FEMUR AND TIBIA. IT...: $29,522
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
GLOBUS MEDICAL Congressional Stock Trading
Members of Congress have traded $GMED stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GMED stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
GLOBUS MEDICAL Analyst Ratings
Wall Street analysts have issued reports on $GMED in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/17/2025
- Truist Securities issued a "Buy" rating on 11/18/2025
- Barclays issued a "Overweight" rating on 11/10/2025
To track analyst ratings and price targets for GLOBUS MEDICAL, check out Quiver Quantitative's $GMED forecast page.
GLOBUS MEDICAL Price Targets
Multiple analysts have issued price targets for $GMED recently. We have seen 9 analysts offer price targets for $GMED in the last 6 months, with a median target of $105.0.
Here are some recent targets:
- Vik Chopra from Wells Fargo set a target price of $104.0 on 02/26/2026
- David Saxon from Needham set a target price of $114.0 on 02/25/2026
- Matt Miksic from Barclays set a target price of $123.0 on 02/25/2026
- Caitlin Cronin from Canaccord Genuity set a target price of $112.0 on 01/09/2026
- Matt O'Brien from Piper Sandler set a target price of $115.0 on 01/08/2026
- Shagun Singh from RBC Capital set a target price of $100.0 on 12/17/2025
- Keith Hinton from Freedom Capital Markets set a target price of $87.0 on 12/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
